LDL cholesterol

Factoring the metabolic X syndrome
Factoring the metabolic X syndromeAlthough there is debate surrounding the definition of metabolic X syndrome in pediatrics and there are few long-term studies of outcomes in children with metabolic syndrome, pediatric metabolic syndrome needs to be on the radar of all pediatricians interested in ensuring a healthy adult life for their patients.
Study: New cholesterol drugs cost 356 times more than genericsA report from the Alliance of Community Health Plans can help get a better sense of how well drugs help patients compared to other treatment options.
PCSK9 inhibitor benefits patients with statin intolerancePCSK9 inhibitor benefits patients with statin intolerance
FDA approves major cholesterol drugThe FDA on August 27 approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment options.
Battle of the cholesterol drugs expectedThis summer, Amgen and Regeneron Pharmaceuticals/ Sanofi will battle it out in the competitive cholesterol market. Repatha and Praluent, respectively, are expected to be approved by the FDA this summer.
Investigational PCSK9 inhibitor lowers LDL-C, may reduce cardiovascular eventsAlirocumab (Praluent), a PCSK9 inhibitor, reduced low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy, according to a study published online in the New England Journal of Medicine.
Studies: Evolocumab shows promise in reducing LDL cholesterol in patients with genetic disorders that cause high cholesterolRecent data from 2 phase 3 studies showed treatment with evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication, resulted in a statistically significant reduction in LDL-C compared to placebo in patients with different types of familial hypercholesterolemia (FH).
Investigational ACL inhibitor shows promise in lowering LDL cholesterolACL inhibitor ETC-1002 (Esperion) met its primary end point of greater LDL-cholesterol lowering from baseline with ETC-1002 compared with ezetimibe, according to a study.
Lower-intensity statins plus bile acid sequestrant considered good option for some heart patients, study findsCombination therapy with a lower-intensity statin and bile acid sequestrant or ezetimibe lowered LDL cholesterol similar to or better than higher-intensity statin monotherapy among patients with high risk for atherosclerotic cardiovascular disease (ASCVD), according to a study published February 11 online in the Annals of Internal Medicine.
Lower-statin combo therapy good option for some heart patientsAmong patients with high ASCVD risk, lower-intensity statin plus a bile acid sequestrant or ezetimibe lowered LDL cholesterol as well as higher-intensity statin mono therapy did.